Get started

MRNA

$MRNA Bearish to Bullish Reversal NASDAQ:MRNA Bearish to Bullish Reversal A "Bearish to Bullish Reversal" in technical analysis for NASDAQ:MRNA suggests a shift in the stock's price movement pattern from a downward trend (bearish) to an upward trend (bullish). This reversal typically occurs after a period of decline, indicating that the stock may be transitioning from a bearish phase to a bullish phase. It could signify a potential turning point in market sentiment, with investors becoming more optimistic about the stock's future prospects. Traders often look for confirmation signals to validate this reversal, such as increased trading volume or positive fundamental developments in the company.
NASDAQ:MRNALong
by AlgoTradeAlert
Moderna Surge as it Dives into Promising Cancer Vaccine TrialsModerna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be attributed to several key factors that are igniting investor enthusiasm and confidence in the company's future prospects. One of the primary catalysts driving Moderna's stock rally is the initiation of a mid-stage clinical trial for its experimental cancer vaccine targeting cutaneous squamous cell carcinoma, a prevalent form of skin cancer. This groundbreaking trial, conducted in collaboration with Merck, underscores Moderna's commitment to pioneering innovative solutions in oncology. In addition to advancements in oncology, Moderna ( NASDAQ:MRNA ) continues to make significant strides in addressing infectious diseases, oncology, and rare diseases. Despite the challenges posed by the endemic market, Moderna ( NASDAQ:MRNA ) reported notable pipeline advancements in its fourth-quarter results. The company anticipates initial regulatory approvals for its RSV vaccine (mRNA-1345) starting in the first half of 2024, further bolstering its position in the market. Moreover, Moderna ( NASDAQ:MRNA ) remains optimistic about its COVID-19 franchise, projecting profitability in anticipated sales scenarios for 2024 and beyond. With approximately $4 billion in product sales expected in 2024, primarily driven by COVID-19 vaccine sales and the launch of its RSV vaccine, Moderna is poised for robust growth in the coming years. Technical Analysis Shares of Moderna ( NASDAQ:MRNA ) is exhibiting a bullish Flag pattern indicating the NASDAQ:MRNA has reacted to the Promising Cancer Vaccine Trials news. With a moderate Relative Strength Index (RSI) of 68.74 NASDAQ:MRNA shares is gaining momentum. Looking ahead, Moderna's pipeline update revealed a promising outlook, with 45 therapeutic and vaccine programs, nine of which are in late-stage development. Notably, the Phase 3 trial of its combination vaccine against seasonal flu and COVID-19 has been fully enrolled, with data expected in 2024. These developments underscore Moderna's commitment to innovation and its potential to deliver groundbreaking therapies to address critical unmet medical needs. In conclusion, Moderna's recent stock rally reflects growing optimism and confidence in the company's innovative pipeline, particularly in the areas of oncology and infectious diseases. With promising clinical trials underway and a robust portfolio of vaccine candidates, Moderna is well-positioned to capitalize on emerging market opportunities and drive long-term value for investors. As the company continues to make strides in pioneering mRNA technology, investors can expect Moderna to remain at the forefront of medical innovation, potentially revolutionizing the treatment landscape for various diseases, including cancer.
NASDAQ:MRNALong
by DEXWireNews
NVAX rises impending an earnings report LONGToday NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings is coming this upcoming week. This week NVAX news release showed it had settled a years long litigation over a failed COVID. In the face of earnings around the corner, was this news release a coincidence or instead a case of excellent executive and legal timing? I will skip the conspiracy discussion. On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock that has been stuck in deeply undervalued territory for a significant time period is remarkable. I have bought far out of the money call options into 2025 and 2026 some only this past month. Those from this month are now up over 250% with 11 and 23 months to go to expiration. I see NVAX as a risky penny medical stock with a high reward potential relative to the risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out the competition when there is an opportunity and do not worry about the government crying monopoly when life-saving and life-extending medical products are involved. Time will tell. I expect insane profits.
NASDAQ:NVAX
by AwesomeAvani
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area of the volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing position here and again the next time I see a dip on the 15-30-minute chart. I look forward to take a piece out of the position after the next earnings report in about 75 days. I have an alert for relative volume when the running mean is exceeded on the 30 minute chart which notify me to take a look at the chart. This is illustrated on this longer time frame chart about the days around earnings but occurs from time to time from other events. As an aside, if NVAX gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be the leading candidate to do a takeover, friendly or otherwise.
NASDAQ:MRNALong
by AwesomeAvani
NVAX- a medical penny stock Buy Weakness LONGNVAX on a 120 minute chart demonstrates a trend down in the past month after a period of consolidation producing the POC line on the volume profile. The MACD shows some bullish divergence. The volume profile has high volume nodes at 4.0 and 5.0 separated by a relative volume void. NVAX fell quickly through that void. It can just as easily rise through it. See the linked article on NVA from TipRanks. Options volume and pricing analysis is that bets are looking at5.0 diligently. Fundamentally, NVAX has been range limited by its focus on COVID but it does have other projects in its pipeline admittedly on various timelines with varying probabilities of capitalizing on them depending on clinical trials FDA approvals and so on. On the imbedded relative strength table as compared with SPY and peers in the pharmaceutical, biotechnology, medical device and healthcare spaces NVAX compares favorably with MRNA its closest peer but is weak compared with most of the others I have selected especially with LLY, which is high-flying from its anti-obesity drug breakout. Device companies Stryker and Intuitive Surgical are quite strong as well. United Healthcare is dominant in the insurance subsector and strong overall. One often effective strategy is to buy when an instrument is oversold and undervalued at a discount. I will buy NVAX here no matter that I have insider connections with one of those medical device companies and a few not on the list. Sentiment only goes so far. I found the article compelling and so Novavax long I go. On a trading site left unsaid my screenname is "Bottom Feeding Grinder". I have an appetite for NVAX found at the bottom right now. This is a reversal/reversion to the mean long trade. It is not without risk. As a penny stock with high volumes, low cost of entry and perhaps low floats, volatility is underscored and exaggerated if a volume inflow gets underway That said, a short squeeze is within the spectrum of possibilities. Enough said for now.
NASDAQ:NVAXLong
by AwesomeAvani
Novavax- NVAX- Medical Technology Vaccine Focused LONGNVAX on the 15 minute chart has been compressing price action volatility into a symmetrical triangle. It in now in a breakout of the triangle and in the process when from undervalued on Monday to the upper trendline and then down to the support trendline and then up again. It passed through the volume profile and its high volume area. In short, it has bullish momentum capped off with a breakout from the high volume area into a bullflag to rest the weekend. I am in this stock going and now is an opportunity to add to the position. If a trader wants to know what I consider to be targets upside, let me know. Medical technology is expected to be among the hottest of subsectors for 2024. NVAX has been beaten down. I believe it has significant upside for the long term. in the short term, earnings are expected on February 28th so this is a trade to consider on that run up. Call options for March 2 or March 16 can be considered.
NASDAQ:NVAX
by AwesomeAvani
Moderna's Surprising Profit Signals Post-Pandemic PivotModerna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause. Unveiling the Numbers: Moderna's ( NASDAQ:MRNA ) fourth-quarter profit stood at a commendable $217 million, or 55 cents a share, defying analyst expectations of a substantial loss. This unexpected triumph was fueled by a combination of factors, including unforeseen deferred revenue and a strategic overhaul in manufacturing operations. The company's ability to navigate challenges and adapt swiftly underscores its agility and forward-thinking approach. Navigating the COVID-19 Landscape: While Moderna's COVID-19 vaccine continues to be its flagship product, generating substantial revenue, the company is strategically diversifying its portfolio. Despite a decline in COVID vaccine sales from 2022 to 2023, Moderna ( NASDAQ:MRNA ) remains steadfast in its commitment to innovation. The imminent approval decision for its respiratory syncytial virus (RSV) shot marks a significant milestone in this diversification strategy, offering a glimpse into the company's post-pandemic roadmap. Looking Beyond COVID: Moderna's ( NASDAQ:MRNA ) ambitious roadmap extends far beyond the realm of COVID-19. With plans to launch its RSV shot in key markets and a robust pipeline of experimental shots targeting influenza, cancer, and cytomegalovirus, the company is poised for a transformative journey. Despite concerns over efficacy declines compared to rival offerings, Moderna's ( NASDAQ:MRNA ) unwavering focus on research and development signals a bold leap into uncharted territories. International Endeavors: Moderna's ( NASDAQ:MRNA ) participation in the EU Health Emergency and Response Authority’s tendering procedure underscores its commitment to global health initiatives. By prioritizing key international markets and aligning with strategic partners, the company aims to broaden its reach and impact. The forthcoming decision on the EU tender is poised to shape the company's trajectory in the global arena, setting the stage for future collaborations and expansions. Charting the Course Ahead: As Moderna ( NASDAQ:MRNA ) reaffirms its 2024 forecast amidst shifting market dynamics, the company remains steadfast in its pursuit of excellence. With a projected $4 billion in sales and a focus on operational execution, Moderna ( NASDAQ:MRNA ) is poised to navigate challenges and seize opportunities in the years ahead. Conclusion: Moderna's ( NASDAQ:MRNA ) unexpected profit surge and strategic roadmap offer a compelling narrative of resilience and innovation in a rapidly evolving landscape. With eyes set on new horizons and a steadfast resolve, Moderna ( NASDAQ:MRNA ) emerges as a beacon of hope in the post-pandemic world.
NASDAQ:MRNALong
by DEXWireNews
Moderna's Road to Recovery Moderna has recently garnered attention for its significant rebound after a challenging 2023. The biotech company, primarily known for its groundbreaking COVID-19 vaccine, is poised for a transformative journey ahead, with a strategic pipeline that extends far beyond pandemic management. This Idea delves into the recent surge in Moderna's stock, the pivotal role of Oppenheimer's upgrade, and the promising prospects that lie ahead. The Resilience of Moderna Stock: Following a tumultuous year in 2023, marked by a 45% dip in stock value, Moderna is experiencing a remarkable resurgence. A recent 15% surge was triggered by Oppenheimer's optimistic upgrade to "outperform." The upgrade reflects the financial firm's confidence in Moderna's ability to diversify its product portfolio, projecting the introduction of five new products by 2026. This shift in sentiment underscores the market's recognition of Moderna's potential to pivot beyond its flagship COVID-19 vaccine. Diversification Beyond COVID-19: Moderna's dependency on COVID-19 vaccine sales took a toll in 2023, prompting the need for diversification. Oppenheimer analyst Hartaj Singh highlights Moderna's promising pipeline, suggesting the potential launch of several products over the next 12 to 18 months. Among these, an experimental vaccine targeting respiratory syncytial virus (RSV) for older adults stands out, with a potential FDA decision in April 2024. The company's experimental flu vaccine, displaying superior immune response in trials, could also secure approval in 2024 or 2025. Additionally, the prospect of an FDA approval for an experimental personalized cancer vaccine further enhances Moderna's growth potential. Financial Outlook and Market Response: Despite a projected dip in COVID-19 vaccine sales in 2024 due to factors like vaccine fatigue, Moderna's overall sales are expected to surge in 2025 and beyond. The company's third-quarter earnings report anticipates revenue to rebound to $4 billion in 2025 after a temporary decline to $4 billion in 2024. Moderna's commitment to launching up to 15 products in the next five years aligns with its goal to diversify revenue streams and minimize reliance on pandemic-related products. Technical Analysis and Investor Sentiment: A crucial aspect of Moderna's recent success lies in its positive technical analysis. Breaking the ceiling of the falling trend in the medium-long term signifies a slower rate of decline. While the stock has met the short-term objective at $86.84, the technical indicators suggest cautious optimism. With support at $70.00 and resistance at $118, the stock appears well-positioned for potential growth. Conclusion Moderna's stock journey reflects a company resilient in the face of challenges, capitalizing on opportunities beyond the pandemic. Oppenheimer's upgrade and the positive technical analysis signal a turning point for Moderna, with a diversified product portfolio offering a hedge against future uncertainties. As the pharmaceutical giant marches towards its goal of launching innovative products, investors are increasingly viewing Moderna as more than just a COVID-19 play, but a promising player in the broader healthcare landscape.
NASDAQ:MRNALong
by DEXWireNews
Moderna’s Stock Boosted by Data From Trial of Melanoma TreatmentModerna Inc.’s stock soared 14% early Thursday to early Friday after the biotech company and partner Merck & Co. announced positive data from a trial of Moderna’s mRNA-4157 in combination with Merck’s blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV). The companies said that after about three years, the combination reduced the risk of recurrence or death by 49% in a Phase 2 trial and the risk of distant metastasis or death by 62%, as compared with Keytruda alone. “As we continue to follow participants in the Keynote-942/mRNA-4157-P201 study, we are excited to see such a robust clinical benefit with mRNA-4157 (V940) as adjuvant treatment in combination with Keytruda in people with resected high-risk melanoma,” said Kyle Holen, senior vice president and head of development in therapeutics and oncology at Moderna. “These data add another positive analysis to the multiple endpoints and subgroups previously assessed in this study,” he said. Technical Analysis NASDAQ:MRNA reached its 1 Month High on the 14th December, 2023 siting the stocks responds to the Positive Data from the Trial of Melanoma Treatment. Moderna’s stock has fallen 50% to date in 2023, while the S&P 500 has gained 22.6%. Although NASDAQ:MRNA is trading near the bottom of its 52-week range and below its 200-day simple moving average, the stock is likewise showing signs of a continual trend which is poise to set foot on a new Resistance level.
NASDAQ:MRNALong
by DEXWireNews
2
Moderna Break of Major Support, Short PotentialThis is a Technical Analysis on Moderna (MRNA) on the 1 Week Timeframe. Current price action shows that we are currently in the process of breaking a MAJOR SUPPORT Zone. We held critical SUPPORT multiple times ABOVE the $115.00 level, for a span of about 26 months. Expressed by the GREEN circles. But notice we havent been able to successfully rally and stay above the "MAJOR RESISTANCE" line. Though the CURRENT candle has not yet closed, which it will end of trading session Monday, the 7th of August. This in my opinion is a critical development. If we CONFIRM below this $115 ish area, the lower range of about $82.00 of the ORANGE zone becomes more likely. The ORANGE zone, or price range between $115 and $82 has barely any market structure or in other words barely any candles. It would be easy for price to fall stright down, in my opinion. This can be an area to take a SHORT position. Another thing to notice since the BLOW of top, we have been forming a DESCENDING TRIANGLE. Its been forming since August 2021, this is NO JOKE. Measuring the target of the end point of descending triangle we get about a 75% drop target. Just remember it doesnt have to play out exactly but its something to consider and keep in the back of the mind. So just to mention: 1st Target = $82 ish area 2nd Target = $57- $47 range Last Target = Descending triangle measured target of $29 ( *Less likely for the time being) RSI has been: 1. printing Lower Highs 2. is currently below the Black Moving average, which i use as an indication of price moving down 3.Is currently in process of ALL TIME RSI LOW, provided we close this weeks candle at current RSI lvl. STOCH RSI -> Setting up for a BEARish cross. This if it occurs and we are below the MAJOR SUPPORT, bearish momentum can push price down. Lastly ADX & DI -> We have RED line cross above Green and pointing up. We need to observe this, this indicates also the BEARISH momentum is coming in. If the BLACK moving average curves up and starts moving towards the RED/GREEN line with RED being on top, this will indicate bearish momentum. CONCLUSION: We are at major cross roads for MRNA. If we don't have any buying occur during Mondays trading session, and we close below MAJOR SUPPORT, it may be time to SHORT MRNA. We have not had any luck trying to break and stay above the "MAJOR RESISTANCE" line. This, along with multiple touches on MAJOR SUPPORT, has made this WEAK (in my opinion). Short targets include the primary, secondary and descending triangle target levels. Indicators are also shaping up to support the current price action. At times like this, it is important to observe further clues of bearish activity, to be patient and take it one step at a time. Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again. If you have any questions, do reach out. Thank you again. DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. When trading always spend majority of your time on risk management strategy.
NASDAQ:MRNAShort
by SafofAllTrades
Covid 2023 - Profiting from CorruptionHello everyone Josh here again. I’m sure by now you’ve already heard mumblings of Covid’s imminent return. We are seeing everything from colleges to hospitals start to implement Covid policies. The news cycle is starting to warn of a dangerous flu season/Covid return. Governments around the world are now updating their Covid policies and sleepy Joe’s White House is still pushing for the mass vaccination and experimentation on of human guinea pigs around the world. With all this being said, it is my idea that we are about to go back into lockdown/full Covid policy mode. Although I wish this was not the case, I do intend to profit from it. Illustrated is the Moderna chart, I use this, as it was one of the first assets I made money off of during the last pandemic, in fact, you can still go back and see my old idea on my page about Moderna when I called it at around sub $60. However, this could’ve been any chart from Amazon and Netflix to hospital sectors, to e-commerce platforms like Shopify. Basically, anything that will go up during a full-scale, pandemic/lockdown. If my gut feeling is right, and we are going to go into a full-scale lock down, it might be one of the easiest plays of the century. During the last pandemic, we saw airlines, cruise lines, casinos and resorts and a myriad of other sectors collapse to unprecedented lows. I expect something similar to happen this time around, to varying degrees of severity. Many people made millions by shorting assets last pandemic, I think we are setting ourselves up for the perfect storm to profit. Look for stocks to long and short. Ignore the noise and make your money off of the lies of the global elite. Below is an AI rendered breakdown of this idea. Thank you so much for reading. Please follow and like my ideas :) Investment Thesis: Navigating Pandemic-Related Market Trends I. Introduction: The investment thesis centers around capitalizing on potential market shifts resulting from pandemic-related policies enacted by governments and corporations globally. II. Market Outlook: Anticipating the implementation of pandemic-related rules and regulations, which could include mask mandates, lockdowns, and travel restrictions. III. Asset Allocation Strategy: A. Long Positions: E-commerce Dominance: As witnessed during the previous pandemic, e-commerce platforms like Amazon thrived. This trend is likely to persist as people turn to online shopping for convenience and safety. Entertainment Streaming: Companies like Netflix benefited from increased demand for home entertainment. Expect this trend to continue, making streaming platforms potentially profitable investments. Pharmaceutical Giants: Pfizer and Moderna played pivotal roles in vaccine development during the Covid pandemic. Their expertise positions them well for potential future vaccine requirements or pharmaceutical innovations. Healthcare Stocks: Hospital and healthcare-related stocks may experience increased demand as health services remain crucial during pandemic periods. B. Short Positions: Travel and Hospitality Sectors: Historical data shows that airlines, cruise liners, resorts, and casinos experienced significant declines during the last pandemic due to travel restrictions and reduced consumer spending. IV. Risk Considerations: While historical patterns suggest certain sectors will benefit and others may decline during pandemics, unforeseen variables can impact market dynamics. Careful monitoring and adaptability are essential. V. Diversification and Hedging: To mitigate risks, consider diversifying your portfolio across industries and asset types. This approach helps balance potential losses from short positions with gains from long positions. VI. Exit Strategy: Regularly reassess the investment landscape, keeping an eye on shifts in policies, vaccination rates, and economic indicators. Be prepared to adjust your positions accordingly to optimize gains or minimize losses. VII. Conclusion: In light of potential pandemic-related policies, a strategic investment approach involves capitalizing on e-commerce, streaming, pharmaceutical, and healthcare sectors, while shorting travel and hospitality sectors. Prudent risk management, diversification, and a proactive exit strategy will be pivotal in navigating the ever-evolving market landscape. Please note that investment decisions involve inherent risks, and it's advisable to consult with a qualified financial advisor before executing any investment strategy.
NASDAQ:MRNA
by Helios_Capital_Investment
BNTX biotech / currency play LONGBNTX a Germany company in the biotechnology and vaccine sectors out of Europe and Germany is looking good on the 2H chart here with a volume profile and an intermediate term VWAP overlaid. Price bounced off the bottom of the high volume area of the volume profile and looks to be ready for a reversion to the mean and even a sling-short move. The target here is the double top M pattern of mid July at 114. The VPT and MACD are confirmatory of a momentum flip making for a long trade entry. I will review the options chain for a suitable options trade with a narrow bid/ask spread, suitable volume and open interest. If I cannot find one I'll take a trade of 10-20 shares of stock with a stop-loss of 105 to back up this trade while NVAX and MRNA are also making moves.
NASDAQ:BNTXLong
by AwesomeAvani
MRNA a medical Technology Stock LONG MRNA is a medical technology company. It is in the vaccine sector and competes ( well) with NVAX and PFE among others. Earnings are upcoming on 8/3 in about a week. On the 30 minute chart it appears to be in a descending wedge pattern which is typically a bottoming with a breakout over and beyond the descending trendline. The relative trend indicator shows the downtrend to be a slow grinding type trend with some minor corrections along the way. As might be expected the RS lines are low in the indicator's channel. I see this as a setup for a pre-earnings play with the expectation that MRNA could breakout above the resistance trend line and move toward the horizontal resistance of the triple top earlier in mid-July. I see medical stocks as a good alternative to technology stocks that may be overextended and stressed by the current financial chaos pressuring the markets. Another approach is a two call options targeting $ 125 expiring 8/11 and running the first until 100% profit or 8/2, the day before the expiration whichever comes first and letting the other run through earnings into the middle of the following week at 8/9. I always like to cut these short of expiration by a few days to diminish the effects of time decay.
NASDAQ:MRNA
by AwesomeAvani
2
Can NVAX rise again?NVAX has had significant down trending over a wide range of time. On the 4H chart it seems to be pivoting from a swing bottom 3-4 days ago. This is accompanied by a cross of the MACD lines under the histogram on that indicator and a flip of volatility on the relative volatility indicator. NVAX has been subject to significant short selling. Price is presently nearly two standard deviations below the mean anchored VWAP set in mid May. Basically it is in deep undervalued oversold territory and now with a rise. The volume profile has a point of control level considerably above the mean VWAP. This is the level with the highest volume of trades showing most trades occurred well above VWAP. This would be traders taking profit and selling or alternatively short sellers opening a position but more likely a combination of them. Price wants to ascend to at least VWAP if not the POC line. My analysis is that any significant rise could begin a squeeze on short positions. Those closing with a buy to cover trade would in effect be synergizing new buyers and add to the bullish momentum, Accordingly, I will open a position early and see if I can get in ahead of a potential short squeeze. While speculative, a narrow stop loss at 6.80 the second band line below the mean VWAP will take a lot of risk off the trade and allow me to be patient comfortably watching the price action.
NASDAQ:NVAXLong
by AwesomeAvani
8